Your Patients Can't Find Adthyza — Here's How You Can Help

You're likely fielding calls from patients who can't fill their Adthyza prescriptions. Since Azurity Pharmaceuticals discontinued Adthyza in November 2025, patients dependent on this natural desiccated thyroid (NDT) medication have been left without their preferred treatment — and they're looking to you for answers.

This guide provides actionable steps your practice can take to help patients transition smoothly, find alternative medications in stock, and maintain continuity of care during a turbulent time for the NDT drug class.

Current Availability: What You Need to Know

Let's start with the facts:

• Adthyza: Permanently discontinued (November 2025). No remaining commercial supply.
• Armour Thyroid (AbbVie): Still being manufactured and distributed, but pharmacy-level availability is inconsistent across regions. Some pharmacies report regular stock; others face frequent outages. Cash price: $35-$43/month.
• NP Thyroid (Acella): Available but supply varies. History of quality concerns (2020-2021 recalls for superpotent tablets). Cash price: $24-$40/month.
• Nature-Throid / WP Thyroid (RLC Labs): Unavailable since 2020.
• Compounded NDT: Available through licensed compounding pharmacies. Pricing typically $30-$60/month. Some compounders report occasional desiccated thyroid powder supply constraints.
• Levothyroxine (generic): Widely available at $4-$30/month. No supply concerns.

Why Patients Can't Find NDT Medications

Understanding the systemic issues helps you counsel patients effectively:

1. Manufacturer Consolidation

The NDT market has shrunk dramatically. With Nature-Throid, WP Thyroid, and now Adthyza gone, only two commercial NDT manufacturers remain (AbbVie and Acella). This concentration means any production or distribution hiccup has outsized impact on supply.

2. FDA Regulatory Uncertainty

The FDA's August 2025 decision to remove all DTE products and reclassify them as biologics has created a chilling effect. Manufacturers face significant uncertainty about whether continued NDT production is economically viable, which affects investment in supply chain and inventory.

3. Distribution Gaps

Even when NDT products are being manufactured, distribution isn't uniform. Chain pharmacies may have allocation limits, and wholesale distributors may prioritize higher-volume medications. This creates geographic pockets where NDT is readily available alongside areas where it's nearly impossible to find.

4. Increased Demand on Remaining Products

Every patient who was taking Adthyza (and before that, Nature-Throid and WP Thyroid) has shifted to the remaining options. This increased demand on a shrinking supply creates pressure at every pharmacy.

What Providers Can Do: 5 Practical Steps

Step 1: Proactively Identify Affected Patients

Run a query in your EHR for all patients with active Adthyza prescriptions. Don't wait for them to call — reach out proactively to schedule transitions. This prevents medication lapses and reduces last-minute emergency calls to your office.

Step 2: Develop a Transition Protocol

Create a standardized approach for your practice:

• For patients open to NDT: Switch to Armour Thyroid or NP Thyroid at equivalent dose. Adthyza 1 grain (65 mg) has similar T4/T3 content to Armour Thyroid 1 grain (60 mg). Order thyroid function tests (TSH, Free T4, Free T3) 4-6 weeks post-switch.
• For patients open to synthetic options: Convert to Levothyroxine (approximately 100 mcg per 1 grain NDT) with or without Liothyronine 5-10 mcg. Monitor at 6 weeks.
• For patients with specific needs: Refer to a compounding pharmacy for custom NDT preparations. Provide a detailed prescription including desired T4/T3 ratio and acceptable inactive ingredients.

Step 3: Help Patients Find Medication in Stock

Direct your staff and patients to Medfinder for Providers — a real-time pharmacy availability tool that shows which pharmacies near the patient currently have their medication in stock. This eliminates the frustrating cycle of calling pharmacy after pharmacy.

Additional sourcing tips to share with patients:

• Try independent pharmacies, which often have different supply chains than major chains
• Consider mail-order pharmacy options for more consistent access
• Call pharmacies early in the week (Monday-Wednesday) when new shipments arrive

Step 4: Prepare Prior Authorizations in Advance

If switching a patient from Adthyza to another NDT product, their insurance may require a new prior authorization. Don't wait for the denial — submit PAs proactively with documentation including:

• History of stable treatment on NDT
• Clinical rationale for continued NDT use
• Recent thyroid function labs
• Statement that Adthyza is discontinued and patient requires therapeutic equivalent

Step 5: Educate Your Team

Ensure your clinical staff — including nurses, medical assistants, and pharmacy liaisons — understand the Adthyza discontinuation and your practice's transition protocol. Common patient questions and their answers:

• "Is Adthyza coming back?" — No, it has been permanently discontinued.
• "Will Armour Thyroid also be removed?" — Its future depends on the FDA's biologics enforcement timeline, currently set for around August 2026.
• "Is generic Adthyza available?" — No. There is no generic equivalent.
• "Can I just take a higher dose of my current medication?" — No. Dose changes must be medically supervised.

When to Consider Alternatives to NDT

While many patients have strong preferences for NDT, certain situations may warrant transitioning to synthetic options:

• Supply uncertainty: If consistent NDT access cannot be guaranteed and the patient's health could be compromised by gaps in therapy
• Cost concerns: Generic Levothyroxine is significantly cheaper ($4-$30/month vs. $24-$60/month for NDT)
• Clinical equivalence: Meta-analyses show most patients achieve adequate symptom control on Levothyroxine. The subset who clearly benefits from NDT is real but represents a minority.
• FDA compliance: If the FDA follows through on removing all commercial DTE products, planning ahead for synthetic alternatives reduces the risk of abrupt transitions later

For a full comparison of alternatives, share this patient-facing resource: Alternatives to Adthyza If You Can't Fill Your Prescription.

Workflow Tips for Your Practice

• Flag NDT patients in your EHR for proactive outreach and monitoring
• Create a templated after-visit summary that explains the Adthyza discontinuation and next steps
• Set up a standing thyroid lab order for 6 weeks post-switch to catch any dosing issues early
• Maintain a list of local pharmacies that reliably stock NDT products — or use Medfinder for real-time data
• Identify 1-2 compounding pharmacies you trust for thyroid preparations as a fallback option

Additional Provider Resources

• Adthyza Shortage: What Providers and Prescribers Need to Know in 2026 — Clinical briefing with timeline, regulatory context, and prescribing guidance
• How to Help Patients Save Money on Adthyza: Provider's Guide — Cost optimization strategies for your patients
• Adthyza Drug Interactions: What to Avoid — Interaction reference for thyroid desiccated products

Final Thoughts

The Adthyza discontinuation is one piece of a larger disruption to NDT access that will likely intensify through 2026 and beyond. The providers who come through this well will be those who plan ahead, communicate proactively with patients, and have flexible prescribing strategies ready.

Your patients trust you to guide them through these changes. Use the resources above — and tools like Medfinder for Providers — to make that guidance as practical and specific as possible.